First-line treatment of chronic myeloid leukaemia-Reference-Cited by-同舟云学术

First-line treatment of chronic myeloid leukaemia

Published:2010-12 Issue:1 Volume:1 Page:15-22
ISSN:2040-6207
Container-title:Therapeutic Advances in Hematology
language:en
Short-container-title:Therapeutic Advances in Hematology

Author:

O'Dwyer Michael¹

Affiliation:

1. Professor of Haematology, National University of Ireland, and Consultant Haematologist, University Hospital Galway, Newcastle Road, Galway, Ireland

Abstract

Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.

Publisher

SAGE Publications

Subject

Hematology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2040620710387981

Reference25 articles.

1. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

2. 24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

3. BCR–ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia

4. Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

5. Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian Learning of Personalized Longitudinal Biomarker Trajectory;Annals of Data Science;2023-08-01

2. Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies;Tyrosine Kinases as Druggable Targets in Cancer;2019-09-25